Eurofins, Cornell team up for blood test on COVID damage

By LabPulse.com staff writers

March 18, 2022 -- Eurofins Viracor recently entered into an exclusive license agreement with Cornell University to commercialize assays for clinically managing COVID-19 and transplant patients impacted by tissue damage and infections.

The Cornell University team recently developed an alternative to biopsy, a blood test to measure organ injury from COVID-19. It uses circulating cell-free DNA (cfDNA) to gauge the damage caused by COVID-19 on cells, tissues, and organs.

The company said the agreement between Eurofins and the university will expand access to a blood-based cfDNA methylation sequencing assay for early detection or prediction of major complications related to allogeneic hematopoietic cell transplantation. The goal is to improve the care of stem cell transplant patients.

In another application, Eurofins intends to commercialize the novel cfDNA test used to identify urinary tract infections in kidney transplant patients, as well as quantify the degree of damage to the kidney and bladder.

Eurofins to conduct U.K. genotyping research program
Eurofins Genomics will genotype 5 million consenting participants in support of the Our Future Health program, a genotyping research program in the U.K.
Eurofins subsidiary launches at-home test for 'forever chemicals'
Eurofins Scientific subsidiary EmpowerDX has launched a new at-home blood test to detect and measure more than 40 per- and polyfluorinated alkyl substances...
Eurofins unit partners with Gingko on COVID-19 testing
Eurofins Scientific subsidiary Clinical Enterprise and Ginkgo Bioworks have formed a partnership to support a federally funded COVID-19 polymerase chain...
Eurofins launches assay to detect omicron variant of COVID
Eurofins Technologies has launched a multiplex reverse transcription polymerase chain reaction assay that can detect the omicron variant of COVID-19.
Eurofins debuts 2 combined tests for COVID/influenza, RSV
Eurofins Technologies has launched two new reverse transcription polymerase chain reaction tests for the simultaneous detection of SARS-CoV-2, influenza...

Copyright © 2022 LabPulse.com

Last Updated 3/18/2022 10:49:12 AM